Lazarus, Jeffrey VMark, Henry EAllen, Alina MArab, Juan PabloCarrieri, PatriziaNoureddin, MazenAlazawi, WilliamAlkhouri, NaimAlqahtani, Saleh AAnstee, Quentin MArrese, MarcoBataller, RamonBerg, ThomasBrennan, Paul NBurra, PatriziaCastro-Narro, Graciela ECortez-Pinto, HelenaCusi, KennethDedes, NikosDuseja, AjayFrancque, Sven MGastaldelli, AmaliaHagström, HannesHuang, Terry T-KIvancovsky Wajcman, DanaKautz, AchimKopka, Christopher JKrag, AleksanderNewsome, Philip NRinella, Mary ERomero, DianaSarin, Shiv KumarSilva, MarceloSpearman, C WendyTerrault, Norah ATsochatzis, Emmanuel AValenti, LucaVillota-Rivas, MarcelaZelber-Sagi, ShiraSchattenberg, Jörn MWong, Vincent Wai-SunYounossi, Zobair M2023-09-052023-09-052023-08-04Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Anstee QM, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Gastaldelli A, Hagström H, Huang TTK, Ivancovsky Wajcman D, Kautz A, Kopka CJ, Krag A, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Terrault NA, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM; on behalf of the Healthy Livers, Healthy Lives Collaborators. A global action agenda for turning the tide on fatty liver disease. Hepatology. 2024 Feb 1;79(2):502-523. doi: 10.1097/HEP.0000000000000545. Epub 2023 Aug 4.0270-91391527-335010.1097/HEP.000000000000054537540183http://hdl.handle.net/20.500.14200/2110Background aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over two rounds a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. Priorities were revised between rounds and in R2 panelists also ranked the priorities within six domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2 the mean percentage of 'agree' responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% 'agree'). The highest ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reducing fatty liver disease prevalence and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.enCopyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.Public health. Health statistics. Occupational health. Health educationGastroenterologyArticle